Preview Newsletter
Xarelto Media Scan 7-2-15
-
Xarelto Bleeding Lawsuits Could Head to Trial Next Summer
Jul 1, 2015 | Bernstein and Lieberhard
By Bernstein and Lieberhard
The federal court overseeing hundreds of Xarelto lawsuits could begin sending cases to trial in August 2016. According to court documents, a bellwether trial program was the subject of discussion during a status conference convened last month in the U.S. District Court, Eastern District of Louisiana, where all federally-filed Xarelto injury claims have been consolidated for the purposes of coordinated pretrial proceedings.50 Xarelto Lawsuits to Be Chosen for Initial Trial Pool. -
Xarelto News Update: Court Meeting Took Place to Identify Potential Plaintiffs for Possible Inclusion in Upcoming Bellwether Trials, Says Lawsuitsettlementnews.com
Jul 1, 2015 | Market Watch
By PR Wire
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that in the most recent news of the Xarelto multidistrict litigation, a court meeting was set in which between 40 and 60 plaintiffs were meant to be identified for specific discovery and the timing was to be addressed in the selection of the upcoming bellwether trials. The court released a case management order in May, addressing several different issues at hand. -
Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference
Jun 30, 2015 | Benzinga
By PRWeb
The progress of more than 500 Xarelto lawsuits currently pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, will be addressed when the Court convenes its next monthly Status Conference. According to the Court's calendar, that conference has now been scheduled for July 9th, at 9:00 a.m. -
Meldofsky Firm LLC Discusses about Xarelto and all of its Controversial Issues
Jun 30, 2015 | PR Buzz
By Meldofsky Firm LLC
The focus on global health issues has become really tremendous as people get wiser and more scrupulous in choosing the products and services, especially when pertaining to health care. One of the most controversial issues that have really captured the attention of a massive number of people is the issues about a famous replacement for Warfarin as a blood thinner agent; the Xarelto. -
Court Overseeing Federal Xarelto Lawsuits Discusses Possible Bellwether Trial Schedule
Jun 28, 2015 | Bio-Medicine
By Bernstein and Liebhard LLP
According to court documents, at least 550 Xarelto lawsuits have been filed in the federal litigation now underway in the Eastern District of Louisiana. The proceeding was established in December 2014 to allow all federally-filed product liability claims involving the drug’s alleged association with uncontrollable bleeding and other serious side effects to undergo coordinated pretrial proceedings. -
Court Overseeing Federal Xarelto Lawsuits Discusses Possible Bellwether Trial Schedule
Jun 28, 2015 | Street Insider
By PRWeb
The parties involved in hundreds of Xarleto lawsuits that have been consolidated in the U.S. District Court, Eastern District of Louisiana recently discussed a possible schedule for the litigation's bellwether trials. -
Considering A Xarelto Lawsuit? 12 Things You Need To Know
Jul 1, 2015 | The Legal Examiner
By Marc Goldich
Xarelto has been linked to increasing the probability of significant uncontrollable bleeding events that result in hospitalization, serious injury and death. If you or a loved one took Xarelto and subsequently suffered one of the aforementioned outcomes, then you may be entitled to compensation from the manufacturers Johnson & Johnson and Bayer AG. -
Xarelto Found to Double Gastrointestinal Bleeding Risk
Jul 1, 2015 | Top Class Actions
By Melissa LaFreniere
As one of the newest blood thinners on the market today, Xarelto has quickly become one of the most prescribed as well. However, a recent study suggests that patients taking the anticoagulant Xarelto have twice the risk of gastrointestinal bleeding when compared to Warfarin (Coumadin) users. -
Dangerous drugs alert: Xarelto linked to higher risk of GI bleeds
Jun 30, 2015 | Clark Perdue
By Clark, Perdue, and List Co LPA
Dangerous drugs alert: A recently published study indicates that patients who use the anticoagulant Xarelto are at a greatly increased risk of experiencing gastrointestinal bleeding. -
UPDATED: Bayer, J&J touting Xarelto trial data to counteract Eliquis surge
Jun 30, 2015 | FiercePharma Marketing
By Carly Helfand
For a while now, Bayer and Johnson & Johnson's ($JNJ) Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot. -
Xarelto Lawsuit
Jun 30, 2015 | American Injury Attorney Group
Xarelto attorneys note that the U.S. Food and Drug Administration (FDA) approved the blood thinner Xarelto in July 2011. Approved uses include reducing the risk of blood clots after hip and knee replacements, treating deep vein thrombosis, pulmonary embolism, and to help reduce the risk of stroke and blood clots in patients with atrial fibrillation. Xarelto lawsuits have resulted from patients’ claims that Xarelto can cause severe, potentially life-threatening internal bleeding, and that drug makers Janssen Pharmaceuticals and Bayer Healthcare failed to disclose the risks associated with Xarelto. -
Illinois Woman Sues Pharma Giants for Xarelto Bleeding
Jun 29, 2015 | Top Class Actions
By Amanda Antell
Illinois plaintiff Beverly C. is suing pharmaceutical companies Bayer and Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), for allegedly causing her to suffer Xarelto bleeding. Beverly claims that in direct result of using the blood thinner, she experienced a life-threatening gastrointestinal bleeding event. -
Realistic Xarelto Internal Bleeding Plans – The Options
Jun 29, 2015 | IT Kit
Less than nine percent in the patients taking Xarelto had had any complications at all. Approximately 1 in every 1000 adults develop DVT annually. Belonging to your class of anticoagulants, Xarelto has serious unwanted side effects leading to even death of patients. 8% to 3% of patients given the enoxaparin and VKA combination experienced a recurrent DVT or PE. ‘I was hoping it would have been a routine check-up and I would definitely drive straight to the exam, but come to locate out it had been not. -
Rudimentary Details of Xarelto Lawsuit Simplified
Jun 27, 2015 | Themashidip.com
By Joella
Apixaban versus Warfarin in Patients with Atrial Fibrillation N Engl J Med. I think what’s promising for me in both situations — reduce costs and this the first is that there was specific events — kind with the perfect storm as they say that come up with clots. Unfortunately, it doesn’t matter what you read within the tabloids evidence is not strong enough for most people including adults with diabetes to rush out and start taking daily doses of full strength aspirin regardless of whether they have had one cardiac arrest or stroke and would like to prevent another. -
Attorney for Complications from Xarelto in Central Illinois
Jun 27, 2015 | The Law Office of Jeff Green
By Jeff Green
The FDA approved the drug Xarelto for use among knee or hip replacement patients to reduce the risk of post-surgical clotting. Following a fast-track regulatory review, the FDA also approved Xarelto for general treatment of DVT and pulmonary embolism. -
Xarelto Bleeding Complications a Perfect Storm, Not So Perfect for Patients
Jun 26, 2015 | Lawyers and Settlements
By Gordon Gibb
Washington, DC: As LawyersandSettlements writer Heidi Turner reminds us, it was just over six months ago, on December 15, 2014, that the Xarelto Lawsuit count stood at about 33 in multidistrict litigation for the new-age blood thinner. As of June 15, that number now stands at 552 and climbing in consolidated cases now under the jurisdiction of the Eastern District of Louisiana.
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
-
Xarelto Bleeding Lawsuits Could Head to Trial Next Summer
Jul 1, 2015 | Bernstein and Lieberhard
By Bernstein and Lieberhard
The federal court overseeing hundreds of Xarelto lawsuits could begin sending cases to trial in August 2016. According to court documents, a bellwether trial program was the subject of discussion during a status conference convened last month in the U.S. District Court, Eastern District of Louisiana, where all federally-filed Xarelto injury claims have been consolidated for the purposes of coordinated pretrial proceedings.50 Xarelto Lawsuits to Be Chosen for Initial Trial Pool
The minutes from that meeting indicate that the Court has proposed creating an initial pool of 50 potential bellwether cases, all of which would be subjected to case-specific discovery. The first two Xarelto trials would begin on August 1, 2016 and August 22, 2016, and each would take place in the Eastern District of Louisiana. The third would be convened on September 12, 2016 in the Southern District of Texas, and the fourth on October 17, 2016 in the Southern District of Mississippi.
Bellwether trials are an important part of any federal multidistrict litigation. The cases chosen for trial are intended to be representative of other lawsuits pending in the proceeding. It is hoped that the outcomes of such rulings will provide insight into the way juries might rule in similar Xarelto lawsuits.
Court documents indicate that more than 500 Xarelto lawsuits are currently pending in the Eastern District of Louisiana, all of which were filed on behalf of individuals who suffered uncontrollable internal bleeding and other serious complications allegedly related to its use. The litigation was established in December 2014, in the expectation that hundreds of similar cases would be filed in federal courts around the country.
All of the Xarelto claims pending in the federal multidistrict litigation similarly accuse the drug’s manufacturers of wrongly positioning the medication as a superior alternative to warfarin. Among other things, they point out that internal bleeding associated with this much older blood thinner can be stopped via the administration of vitamin K. By contrast, there exists no approved remedy to reverse Xarelto bleeding side effects.Discuss Your Xarelto Claim with an Attorney Today
If you or a loved one took Xarelto and experienced uncontrollable internal bleeding, stroke, deep vein thrombosis, or pulmonary embolism, it’s important that you discuss your legal rights with an attorney as soon as possible. To arrange for a free case review with Bernstein Liebhard LLP, please call (888) 979-1182 today.
-
Jul 1, 2015 | Market Watch
By PR Wire
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that in the most recent news of the Xarelto multidistrict litigation, a court meeting was set in which between 40 and 60 plaintiffs were meant to be identified for specific discovery and the timing was to be addressed in the selection of the upcoming bellwether trials. The court released a case management order in May, addressing several different issues at hand. Specific deadlines were set for pre-trial processes so everything could move forward accordingly. The federal multidistrict litigation (MDL) is being overseen in the U.S. District Court in the Eastern District of Louisiana (in re:Xarelto Products Liability Litigation)(in re:No. 2592).
According to court documents, there are currently more than 300 lawsuits filed over Xarelto in the federal litigation in Louisiana, with an additional approximate 160 cases as of now with similar claims pending in Pennsylvania's mass tort proceeding. Lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, include claims of serious health problems and even death as a result of uncontrollable bleeding events. There is no known antidote at this time, according to experts.
Chris Janish, CEO of MTS, commented on the recent announcement in the Xarelto multidistrict litigation, "The Xarelto litigation is a litigation that is starting to pick up steam and could reach 1,000 claims in the future. It is a positive sign that the court is already moving to identify possible bellwether cases to keep the litigation moving in a positive direction."
MTS is ready and able to assist those who need lawsuit help with finding a qualified Xarelto law firm or Xarelto lawyer to provide a free evaluation on their specific case. To learn more about MTS' services involving Xarelto, Pradaxa, or other blood thinner litigations, please visit: http://www.lawsuitsettlementnews.com/pradaxa-all-blood-thinner-cases
If you already have an attorney and have filed a lawsuit and need a lawsuit funding cash advance, not to be confused with a lawsuit loan or pre-settlement loan, Lawsuit Settlement News can assist you with these services. Injured parties from Pradaxa or Xarelto usage and/or complications can apply for up to $50K in pre-settlement or settlement lawsuit funding. For a full list of the services that the company provides, visit: http://www.lawsuitsettlementnews.com/about-our-products-and-services
If you, or a loved one, have been injured by Xarelto or Pradaxa and need lawsuit money or lawsuit help, including finding a Xarelto or Pradaxa law firm, call:877.571.0405.
You may also fill out a quick application online at: www.lawsuitsettlementnews.comand an agent will contact you shortly.
-
Jun 30, 2015 | Benzinga
By PRWeb
The progress of more than 500 Xarelto lawsuits (http://www.xareltolawsuit2015.com/) currently pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, will be addressed when the Court convenes its next monthly Status Conference. According to the Court's calendar, that conference has now been scheduled for July 9th, at 9:00 a.m. (In Re: Xarelto Products Liability Litigation, No. 2592)
"Our Firm is representing Xarelto lawsuit plaintiffs in this proceeding, and we expect that this conference will address matters relevant to their claims. Those matters could include the selection of cases for bellwether trials, as the litigation is preparing to embark on that process. Issues affecting discovery and timetables for depositions are also likely to be discussed," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered life-threatening internal bleeding and other dangerous complications related to its use.
Xarelto Litigation
According to court documents, Xarelto is a new-generation anticoagulant that was approved by the U.S. Food & Drug Administration in 2011. Like other blood thinners, the medication can cause episodes of serious internal bleeding. However, unlike an older anticoagulant called warfarin, there is currently no approved antidote to reverse Xarelto bleeding. The drug's label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*Court records indicate that at least 550 Xarelto lawsuits have been filed in the Eastern District of Louisiana, where federally-filed product liability claims involving the drug's alleged association with uncontrollable internal bleeding and other complications have been consolidated for the purposes of pretrial proceedings. All of the lawsuits similarly allege that the manufacturers of Xarelto failed to provide patients and doctors with adequate warnings regarding its risks, and wrongly positioned the medication as a superior alternative to warfarin. Among other things, plaintiffs point out that internal bleeding associated with warfarin can be reversed via the administration of vitamin K.
Individuals who allegedly experienced serious complications related to Xarelto may be entitled to compensation for medical bills and other damages incurred as a result of their injuries. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP's website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf, FDA, March 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003. -
Meldofsky Firm LLC Discusses about Xarelto and all of its Controversial Issues
Jun 30, 2015 | PR Buzz
By Meldofsky Firm LLC
The focus on global health issues has become really tremendous as people get wiser and more scrupulous in choosing the products and services, especially when pertaining to health care. One of the most controversial issues that have really captured the attention of a massive number of people is the issues about a famous replacement for Warfarin as a blood thinner agent; the Xarelto.
There have been an immense number of people who have filed legal claims because of the devastating outcomes of theXarelto side effects to patients who have undergone treatment with the drug. In fact, there have been more or less 430 lawsuits filed against the manufacturer of the drugs. The controversial issue basically revolved around the fact that there have been very promising claims especially how the drug was advertised, however, the promising potentials and effectiveness of the drug has become a blur with all those adverse effects of the drugs on most of its users.
Another controversy about Xarelto is that unlike other anticoagulants like the Warfarin, the manufacturer has not given any information about the antidote in case the Xarelto side effects take into action. And for severe adverse effects, there will be no other way to reverse the effects of the drug. With Xarelto’s marketing strategy, the issue of downplaying about the risks of using the drug has also unearthed.
Furthermore, there have also been issues about having to recall around 13,500 bottles of Xarelto because of bacterial contamination found in one sample. As stated on the Food and Drugs enforcement Report, the drug manufacturers confirmed the contamination of the drug after a patient filed his/her complaint. The producers of the drug have voluntarily commenced the nationwide recall of all of the products that came from their plant in Gurabo, Puerto Rico where the said contaminated bottles came from. But actually, the plant was one that has been upgraded by J&J two years ago. The company said that they are very much willing to recall all the 13, 500 bottles of Xarelto to show their commitment to ensuring the quality of their products.
Although Xarelto is still viable in the market, people some people are still in doubt about of the credibility of the products because of its involvement in various controversial issues. But, the fact is that Xarelto continues to be one of the leading anticoagulant medications in the market up to this day.
About Meldofsky Firm LLC
The Meldofsky Firm LLC is a law firm located in Lake Forest, CA aims to help people who are in need for legal assistance. The law firm is manned by exceptional professional competent lawyers who provide their clients with legal representations even of clients residing outside California. The Meldofsky Law Firm provides legal assistance with claims and compensation in cases of medication-related court cases like the Xarelto Lawsuit. -
Court Overseeing Federal Xarelto Lawsuits Discusses Possible Bellwether Trial Schedule
Jun 28, 2015 | Bio-Medicine
By Bernstein and Liebhard LLP
Threatening internal bleeding and other dangerous complications related to its use.
Xarelto Litigation
According to court documents, at least 550 Xarelto lawsuits have been filed in the federal litigation now underway in the Eastern District of Louisiana. The proceeding was established in December 2014 to allow all federally-filed product liability claims involving the drug’s alleged association with uncontrollable bleeding and other serious side effects to undergo coordinated pretrial proceedings. Among other things, plaintiffs allege that the manufacturers of Xarleto wrongly positioned the blood thinner as an improvement over warfarin, an anticoagulant that has been in use for decades. Among other things, the lawsuits point out that unlike Xarelto, internal bleeding associated with warfarin can be reversed with the administration of vitamin K.According to court documents, Xarelto is a new-generation anticoagulant that was approved by the U.S. Food & Drug Administration in 2011. The drug’s label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*
Individuals who experienced dangerous internal bleeding and other serious complications allegedly related to the use of Xarelto may be entitled to join this litigation. Learn moreabout filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
-
Court Overseeing Federal Xarelto Lawsuits Discusses Possible Bellwether Trial Schedule
Jun 28, 2015 | Street Insider
By PRWeb
The parties involved in hundreds of Xarleto lawsuits (http://www.xareltolawsuit2015.com/) that have been consolidated in the U.S. District Court, Eastern District of Louisiana recently discussed a possible schedule for the litigation's bellwether trials. According to a Minute Entry issued after the Court's June 22nd Status Conference, four bellwether trials would be convened beginning with the first trial on August 1, 2016, followed by a second trial on August 22, 2016, a third trial on September 12, 2016, and the fourth trial on October 17, 2016. The first two trials would be held in the Eastern District of Louisiana, while the third would take place in the Southern District of Texas, and the fourth in the Southern District of Mississippi. The four bellwether cases would be chosen from a discovery pool that will include 50 Xarelto lawsuits. (In Re: Xarelto Products Liability Litigation, No. 2592)
"Our Firm is representing Xarelto lawsuit plaintiffs in this proceeding, and we are pleased that the Court is moving forward with a bellwether trial plan. Bellwether trials are an important milestone in any multidistrict litigation, and are intended to provide insight into how juries might rule in similar cases included in the proceeding," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered life-threatening internal bleeding and other dangerous complications related to its use.
Xarelto Litigation
According to court documents, at least 550 Xarelto lawsuits have been filed in the federal litigation now underway in the Eastern District of Louisiana. The proceeding was established in December 2014 to allow all federally-filed product liability claims involving the drug's alleged association with uncontrollable bleeding and other serious side effects to undergo coordinated pretrial proceedings. Among other things, plaintiffs allege that the manufacturers of Xarleto wrongly positioned the blood thinner as an improvement over warfarin, an anticoagulant that has been in use for decades. Among other things, the lawsuits point out that unlike Xarelto, internal bleeding associated with warfarin can be reversed with the administration of vitamin K.According to court documents, Xarelto is a new-generation anticoagulant that was approved by the U.S. Food & Drug Administration in 2011. The drug's label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*
Individuals who experienced dangerous internal bleeding and other serious complications allegedly related to the use of Xarelto may be entitled to join this litigation. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP's website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf, FDA, March 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092 -
Considering A Xarelto Lawsuit? 12 Things You Need To Know
Jul 1, 2015 | The Legal Examiner
By Marc Goldich
Xarelto has been linked to increasing the probability of significant uncontrollable bleeding events that result in hospitalization, serious injury and death. If you or a loved one took Xarelto and subsequently suffered one of the aforementioned outcomes, then you may be entitled to compensation from the manufacturers Johnson & Johnson and Bayer AG. As recently reported byBloodThinnerHelp.com, there are over 400 Xarelto lawsuits filed in the federal MDL. This number is expected to rise steadily in the coming months.
If you are considering filing a Xarelto lawsuit, the following 12 points are useful to know about the litigation:The FDA approved Xarelto (rivaroxaban) for several indications over the years. It was initially approved for preventing blood clots and DVT primarily in patients who underwent some hip or knee replacement surgeries. It was also approved to prevent blood clots in patients suffering from the prominent heart condition, atrial fibrillation. One of its more recent approvals was for the general reduction of incidents of blood clots in patients suffering from acute coronary syndrome.Xarelto (rivaroxaban) is manufactured by European drug conglomerate Bayer AG, who have US operations. Johnson & Johnson are also a key player in introducing Xarelto to the US by way of supporting the patent applications and FDA approval process through its research branch Janssen. The US Headquarters for these companies are in New Jersey and New York.In 2011, Xarelto (rivaroxaban) was approved for sale in the United States of America for the first time.To date, the manufacturers of the drug have not advised the medical community as to what medical intervention is needed to reverse the effects of Xarelto. With no known antidote, an internal or serious external bleed can cause death or serious injury. There have been reports that a startup company has found a reversal agent, however this has not yet been approved. Other blood thinners like Warfarin are reversed through taking Vitamin K, which assists with coagulation.During testing of Xarelto, a study revealed that more than 16,000 (73% of study subjects) reported an adverse side effect.The Food and Drug Administration has issued a warning that the premature discontinuance of Xarelto (Rivaroxaban) increases the risk of blood clots.Xarelto is considered to be a resounding success financially for its manufacturers. In 2013 they reported sales of $1.4 billion.In January 2014 – the first Xarelto lawsuit was filed alleging that the drug caused uncontrollable bleeding that lead to the death of the plaintiff’s husband.Since then hundreds of lawsuits have been filed. All have an unfortunate common theme: uncontrollable bleeding lead to a serious injury, hospitalization, or death.The most common injuries named in lawsuits are: pulmonary embolism, heart attack, stroke, brain hemorrhage, rectal bleeding, vaginal bleeding, epidural hematoma, and gastrointestinal bleeding.So many federal lawsuits have been filed that a mechanism known as a MDL has been formed to streamline the pretrial and discovery phases of the litigation. For federal cases, they will be transferred to federal court in Louisiana.In addition, many lawsuits were filed in Pennsylvania, and the court of common pleas have followed a similar strategy to process the discovery and pretrial motions via a consolidated mass tort group.
We hope the above gave you some background on the Xarelto litigation and where it stands as of today.
If you have any questions or comments, feel free to leave them below or you can reach me by using the contact information below:
Contact Information:
Name: Marc Goldich, Esq.
Phone: 866-425-8902
-
Xarelto Found to Double Gastrointestinal Bleeding Risk
Jul 1, 2015 | Top Class Actions
By Melissa LaFreniere
As one of the newest blood thinners on the market today, Xarelto has quickly become one of the most prescribed as well. However, a recent study suggests that patients taking the anticoagulant Xarelto have twice the risk of gastrointestinal bleeding when compared to Warfarin (Coumadin) users.
Gastrointestinal bleeding is a painful condition that often requires blood transfusions and lengthy hospital stays. Xarelto users who have filed lawsuits after experiencing Xarelto bleeding often allege that the drug manufacturer knew of the unreasonably dangerous bleeding risks but did not fully warn consumers or the medical community.
A recent study published in the British Medical Journal analyzed more than 45,000 patients to determine if there is a greater internal bleeding risk associated with the new generation blood thinner Xarelto or the more traditional anticoagulant Warfarin.
Researchers discovered that when comparing the two medications, Xarelto carries more than twice the risk of gastrointestinal bleeding.New Generation of Blood Thinners
Xarelto joined Eliquis and Pradaxa in 2011 as one of the “new generation of blood thinners” thought to replace Warfarin, which has dominated the anticoagulant market for more than 50 years.
Xarelto was initially approved for reducing the risk of blood clots and strokes in patients undergoing knee or hip replacement surgeries. Since then, Xarelto has also been approved to treat deep vein thrombosis and pulmonary embolism.
The new generation blood thinner Xarelto was marketed by Bayer Health Pharmaceuticals, Janssen Pharmaceuticals, and Johnson & Johnson as a more convenient medication when compared to Warfarin because Xarelto does not require any dietary restrictions or monthly blood tests. However unlike Warfarin, if a patient experiences Xarelto internal bleeding, there is no known antidote to stop it.
Warfarin (Coumadin) users who have a bleeding incident can be given a dose of vitamin K to control the bleeding. Xarelto users who suffer from internal bleeding have to undergo blood transfusions until the medication is out of their system.Xarelto Side Effects
With more than 11 million prescriptions filled in the United States so far, Xarelto is considered the top blood thinner in its class. However, thousands of Xarelto consumers have reported to the FDA that the medication caused life-threatening side effects. Of those reports, hundreds claim Xarelto resulted in a hemorrhage-related death.
Some of the Xarelto side effects reported by consumers include:Abdominal bleedingAbnormal liver functionGastrointestinal bleedingBrain hemorrhagingReduced platelet levelsLow blood pressureBruisingEdemaRectal BleedingHeadacheMuscle painRapid heartbeatDizzinessHemorrhaging in the eyesNose bleedsXarelto Bleeding Lawsuits
Numerous Xarelto bleeding lawsuits have been filed across the nation by plaintiffs who claim that the drug manufacturers intentionally hid the risk of serious side effects from consumers. In addition, Xarelto lawsuits often claim that plaintiffs were not cautioned that should a bleeding event occur, there is no reversal agent to stop it.
Most of the time, filing a Xarelto lawsuit is the only way to obtain financial compensation for physical and emotional damages caused by gastrointestinal bleeding. Contact a Xarelto attorney to find out if you can join a Xarelto class action lawsuit.
-
Dangerous drugs alert: Xarelto linked to higher risk of GI bleeds
Jun 30, 2015 | Clark Perdue
By Clark, Perdue, and List Co LPA
Dangerous drugs alert: A recently published study indicates that patients who use the anticoagulant Xarelto are at a greatly increased risk of experiencing gastrointestinal bleeding.
The new study was published in the British Medical Journal. Over 45,000 Xarelto patients were included in that study, the goal of which was to compare Xarelto with Warfarin. Researchers concluded that the risk of gastrointestinal bleeding could be as much as double when compared to Warfarin. Researchers stated, "we cannot rule out a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) compared with Warfarin."
Xarelto is manufactured by Bayer Healthcare and Janssen, a Johnson & Johnson subsidiary. First approved by the Food and Drug Administration in 2011, Xarelto has become one of the most prescribed prescription drugs in the United States with over 11 million prescriptions written.
Xarelto was first approved for use in preventing blood clots associated with knee and hip implant surgeries. In addition to these approved applications, Xarelto has been used to treat pulmonary embolisms and deep vein thrombosis.
While Xarelto does not require routine blood testing and dietary restrictions like Warfarin, it carries risks in addition to a higher incidence of serious bleeding. Unlike Warfarin, administration of vitamin K will not reverse hemorrhaging. There is no antidote for hemorrhaging caused by Xarelto.
Xarelto is one of several dangerous drugs used for anticoagulation therapy. Pradaxa, manufactured by Boehringer Ingelheim, entered the market one year before Xarelto. More than 4,000 lawsuits were filed against Boehringer Ingelheim alleging serious bleeding injuries. Those claims have been settled for $650 million.
The Ohio pharmaceutical injury attorneys at Clark, Perdue & List successfully represented individuals injured by Pradaxa and are currently representing individuals injured by Xarelto. If you or a loved one has been injured by Xarelto, contact Clark, Perdue & List.
-
UPDATED: Bayer, J&J touting Xarelto trial data to counteract Eliquis surge
Jun 30, 2015 | FiercePharma Marketing
By Carly Helfand
For a while now, Bayer and Johnson & Johnson's ($JNJ) Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.
As Bayer's management acknowledged last week, "the impression that Eliquis is a better drug exists in the marketplace," Bernstein analyst Ronny Gal wrote in a note to investors. But the way the German pharma's leaders see it, it's "wrong."
Xarelto trials were done in the most severe patients, Bayer told Gal, which helped Eliquis--a collaboration between Pfizer ($PFE) and Bristol-Myers Squibb ($BMY)--come out looking stronger. And to combat the idea that Eliquis works better, Bayer this month kicked off a campaign to educate the market on the trial data differences.The Biotech Primer: An insider's guide to the science driving the biotech and pharma industries
This 200-page book takes an in-depth look at the biotech industry and the science that drives it. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come - and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends.
Not too long ago, Bayer and J&J didn't have much to worry about when it came to Eliquis. Despite its rosy trial data, the Pfizer/BMS therapy got off to a sluggish start, well underperforming analysts' early launch expectations.
Now, though, things have turned around for the third-to-market med, with DTC ads and beefed-up sales efforts helping its top-line haul grow to $774 million last year--a far cry from the $146 million it posted the year prior.
And there's new competition in Daiichi Sankyo's Savaysa, too. While that treatment's black box safety warning renders it "not a realistic alternative" to Xarelto, Daiichi could get aggressive with pricing, meaning Xarelto "will have to give some rebates in the U.S.," Gal noted.
Still, Bayer and J&J need not worry too much. More prescriptions are written for Xarelto each week in the U.S. than all of its next-gen competitors combined, a spokesman for J&J's Janssen unit told FiercePharmaMarketing in an emailed statement. Plus, "pricing and access should still continue to be strong," Gal wrote, and the pair's extensive clinical trial program is working to make sure Xarelto keeps the lead in label indications. Both of those will help the drug maintain a hefty piece of the market-share pie, he predicted.
After the management meeting, "we came away less concerned for Xarelto," he wrote. "But it would be nice upside if the competitive message gains traction."
-
Jun 30, 2015 | American Injury Attorney Group
Xarelto attorneys note that the U.S. Food and Drug Administration (FDA) approved the blood thinner Xarelto in July 2011. Approved uses include reducing the risk of blood clots after hip and knee replacements, treating deep vein thrombosis, pulmonary embolism, and to help reduce the risk of stroke and blood clots in patients with atrial fibrillation. Xarelto lawsuits have resulted from patients’ claims that Xarelto can cause severe, potentially life-threatening internal bleeding, and that drug makers Janssen Pharmaceuticals and Bayer Healthcare failed to disclose the risks associated with Xarelto.
If you or someone you love has suffered severe side effects or complications after taking Xarelto, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free consultation that is confidential and without any obligation on your part. If you choose to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney. The time to pursue a claim is limited, so contact us today.
Allegations Brought Against the Drug Maker
Thousands of adverse reactions have been reported to the FDA regarding patients who took Xarelto. In the majority of these claims, Xarelto is listed as a chief factor in the subsequent injury or illness.
Allegations from Xarelto claims that have been filed against the drug makers include:Xarelto causes severe and potentially life-threatening internal bleeding, including brain hemorrhaging, gastrointestinal bleeding, and deathThe drug makers failed to disclose potential dangers of the drug, which would have allowed people to make an informed decision before using it.Xarelto is inherently defective due to the lack of antidote should bleeding complications arise
It is the responsibility of drug makers to provide drugs that are safe. If there are potential dangers or health risks of a drug, warnings must be provided so that patients can make informed decisions regarding its use. Failure to do so could pose a dangerous risk for which the drug maker could be liable if a patient is injured.Injured Patients May Be Entitled to Compensation
Patients who have suffered complications after taking Xarelto may be able pursue claims for compensation, including medical expenses, loss of income or ability to work, and pain, suffering, and mental anguish resulting from an injury.
If a patient dies from complications following the use of Xarelto, family members may be able to pursue claims for the wrongful death of their deceased loved one. Wrongful death damages can include mental anguish resulting from the loss of a loved one, medical expenses that can be attributed to the fatal injury, and loss of companionship or financial support.The Time to Pursue a Claim is Limited. Contact Us Today.
If you or a loved one suffered complications after taking Xarelto, including severe internal bleeding, contact the American Injury Attorney Group today. We offer free, confidential consultations in which we can answer your questions and inform you of your options. If you wish to pursue a claim, we can connect you with an affiliated Xarelto attorney. You have a limited time in which you can pursue a claim, so contact us today.
-
Illinois Woman Sues Pharma Giants for Xarelto Bleeding
Jun 29, 2015 | Top Class Actions
By Amanda Antell
Illinois plaintiff Beverly C. is suing pharmaceutical companies Bayer and Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), for allegedly causing her to suffer Xarelto bleeding. Beverly claims that in direct result of using the blood thinner, she experienced a life-threatening gastrointestinal bleeding event.
Beverly is one of millions of Americans who are in need of blood thinners due to a certain clotting injury, atrial fibrillation. The plaintiff was prescribed Xarelto on July 11, 2012, to reduce her chances of suffering stroke and prevent other possible clotting complications. During her time on Xarelto, Beverly followed all prescription instructions as well as followed the advice of her physician, the Xarelto lawsuit alleges.
Despite her diligence, Beverly allegedly suffered a serious gastrointestinal bleeding event on May 25, 2013. She had to be admitted into hospital care and had to remain under heavy monitoring until the doctors stabilized the bleeding. Upon learning that she had been prescribed Xarelto, her physicians quickly noted that the anticoagulant most likely contributed to her life-threatening bleeding event, according to the Xarelto lawsuit. It was not long after the bleeding event that Beverly learned that there was no available stopping agent on the market for Xarelto bleeding events, and it was was not mentioned on the drug’s label.
Currently, Beverly must contend with a weakened physical state and be on the lookout for a possible gastrointestinal bleeding recurrence. Beverly states that if she had known about the possibility of Xarelto bleeding, then she never would have agreed to take the drug.
Therefore, she is filing legal action against Janssen and Bayer for failing to protect her from the dangers of their product and for failing to notify her physicians of these risks. Beverly’s lawyers state that the pharmaceutical companies had the civil responsibility of warning her and other Xarelto patients of all possible Xarelto side effects, because they rely on the accuracy of the given information.
For being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous drug, Beverly is suing Janssen Pharmaceuticals and Bayer Pharmaceuticals. The charges include: negligence, false advertising, concealing information, and misrepresenting a product.Xarelto Bleeding Complications
Xarelto was approved by the FDA in 2011 as another treatment option to patients suffering from atrial fibrillation or to patients who had recently undergone knee surgery and were very prone to clotting. Similar in design and use to its predecessor, Pradaxa, Xarelto was released as a joint effort between Bayer and Johnson & Johnson to try their luck in the lucrative anticoagulant market.
This proved to be a successful venture for Bayer and Johnson & Johnson, as Xarelto quickly took the place on the top of the anticoagulant market, earning millions in profit for both companies. Unfortunately, it was not long after Xarelto was released that it was discovered to have the same design flaws as Pradaxa.
Similar to its predecessor, Xarelto patients found that they needed hospital intervention in case they suffered an internal bleeding event. Like Pradaxa, there is currently no stopping agent and Xarelto does not require patients to regularly see their doctors for dose adjustments. While the convenience of a single dose was one of Xarelto’s main selling points, many doctors believe that dosage adjustments would have prevented many bleeding events.
Unfortunately this is not the case, as thousands of injured patients who had previously taken Xarelto are filing legal action against the companies. They accuse the companies of deliberately concealing this vital safety information in order to protect Xarelto’s market value.
The Xarelto Lawsuit is In Re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.
-
Realistic Xarelto Internal Bleeding Plans – The Options
Jun 29, 2015 | IT Kit
Less than nine percent in the patients taking Xarelto had had any complications at all. Approximately 1 in every 1000 adults develop DVT annually. Belonging to your class of anticoagulants, Xarelto has serious unwanted side effects leading to even death of patients. 8% to 3% of patients given the enoxaparin and VKA combination experienced a recurrent DVT or PE. ‘I was hoping it would have been a routine check-up and I would definitely drive straight to the exam, but come to locate out it had been not.
But it is still an amazing advance to suddenly have 4 options for anti-coagulation of patients in comparison with the single choice available for the last half a century. Zofran (ondansetron) is a medication manufactured by Glaxo – Smith – Kline which is prescribed for the prevention of nausea and vomiting associated with cancer treatments such as radiation therapy, chemotherapy and surgery. I’m not sure if any of you’re familiar with Serena Williams and what happened to her, but it was essentially the exact same thing. The maximum effective dose to lessen strokes also required monitoring by drawing blood to determine the likelihood of internal bleeding. ‘Xarelto is the initial oral anti-clotting drug approved to take care of and decrease the recurrence of blood clots since the approval of warfarin nearly 60 years ago,’ said Richard Pazdur, M.
How enough time is your lawyer anticipating on devoting for a case. Blisters getting the contagious virus become painful ulcers and deep sores from the buttocks, scrotum, rectum, cervix, or vagina, and will build excretion painful. Rivaroxaban is recommended as an option for treating DVT and preventing recurrent DVT and Pulmonary Embolism Thromboembolism (PET) after a diagnosis of acute DVT in adults. It showed better efficacy at preventing stroke, and equal rate of intra-cranial bleeding as warfarin. Clinical-effectiveness data from the trial comparing Rivaroxaban with Enoxaparin and a vitamin K antagonist in those with venous DVT and PET was applied inside NICE decision-making as was Enoxaparin along with a vitamin K antagonist because key comparator. To find additional details on xarelto lawyer kindly visit xarelto internal bleeding. This disorder, in the event the upper chamber with the heart does not beat in a very regular pattern, is amazingly common. The lawyer you choose to represent you should be one that is easily reachable by phone. ‘Science has not yet yet told us that certain dose of aspirin is better compared to the other. But, it have to be emphasized that all three agents (dabigatran, rivaroxaban and apixiban) were far better at preventing stroke compared to warfarin, and so one may infer that essentially, the three would decrease mortality eventually. Oilfield Injuries and deaths can occur in connection with oil and gas development in all stages of exploration, drilling, production and transportation.
Monitoring signs of “too thin” blood are; unexplained bruising, nose bleeds that are difficult to halt, or blood inside the toilet. Medical conditions which can increase the risk for DVT include some kinds of cancer, trauma, antiphospholipid syndrome, later years, surgery, immobilization (just like bed-rest, orthopedic casts, and sitting on long flights), oral contraceptives, pregnancy, the postnatal period, and genetic factors for example a non-O blood type. Here square look at the causes of Causes of Herpes infections: There square measure two viruses that will manufacture what’s sometimes generally known as as herpes: herpes virus sort one (HSV-1) and herpes simplex virus sort two (HSV-2). The drug does not have access to to be monitored (actually, is not monitored, because it doesn’t affect the INR), doesn’t always have any drug interactions, and was shown to relieve stroke in patients better than warfarin inside RE-LY study of 18,113 people who have atrial fibrillation, and in addition reduced the rate of intra-cranial hemorrhage, a very scary risk when the blood clotting is slowed, and so the chance of abnormal bleeding increases. This new drug carries the “black box warning’ one of the most serious warning in the FDA.
-
Rudimentary Details of Xarelto Lawsuit Simplified
Jun 27, 2015 | Themashidip.com
By Joella
Apixaban versus Warfarin in Patients with Atrial Fibrillation N Engl J Med. I think what’s promising for me in both situations — reduce costs and this the first is that there was specific events — kind with the perfect storm as they say that come up with clots. Unfortunately, it doesn’t matter what you read within the tabloids evidence is not strong enough for most people including adults with diabetes to rush out and start taking daily doses of full strength aspirin regardless of whether they have had one cardiac arrest or stroke and would like to prevent another. Know what general legal area your case is in, and narrow your pursuit for a legal professional within that specialization to locate someone with focused training and experience. For read more about atrial fibrillation from Spectrum Health.
Together, DVT and pulmonary embolism might be seen as a single disease process generally known as venous thromboembolism. The article below includes useful tips to aid you make it happen goal. The INR can also be affected by other drugs the patient is taking. Talk about your expenses and if you’ll be able to work out a payment plan. I known as the doctor and went and got an ultrasound.
A total of 9,478 patients with DVT or PE were randomly allotted to receive Xarelto, a variety of enoxaparin plus a vitamin K antagonist (VKA), or possibly a placebo. Pretty much right where the boot type of constricted my calf. At first I thought maybe I just bruised my calf or something wearing the boot understanding that was a lttle bit optimistic. These goals could be reached by altering lifestyle habits (such as reducing one’s intake of fats and sugars since they can be aware in the nutritional content of foods you eat), through taking prescribed medications, or both. Lawyers are often the subject of a great many jokes, and none of them are very kind to the profession. To find further details on xarelto lawsuit please go to weebly.com. Going forward, just about every doctor I’ve met with has just about had the similar conclusion, which can be three months of anti-coagulation and then you’re off. At the end with the day it had been originally rat poison. In comparison to its DVT, prevention is superior to cure here are my methods for DVT prevention. But why should you be the one to suffer for the wrong doings of the other, rather you should strive to claim the just compensation you deserve, for the loss you have suffered though legal modes. If you have been injured by this drug, you likely have many questions about filing a Xarelto lawsuit.
Gibson tested the drug with many 15,5000 patients have been all set to go out of the hospital or had recently been released, all after having either had a heart attack or other heart related ailment. Do not get caught up in false promises created by greedy lawyers. You will hear people speaking about and INR between 2 and 3 because the aim for patients on warfarin. The attorneys first make an effort to negotiate for any settlement. Did you have to convince Michael Waltrip Racing and Aaron’s to be with you.
-
Attorney for Complications from Xarelto in Central Illinois
Jun 27, 2015 | The Law Office of Jeff Green
By Jeff Green
The FDA approved the drug Xarelto for use among knee or hip replacement patients to reduce the risk of post-surgical clotting. Following a fast-track regulatory review, the FDA also approved Xarelto for general treatment of DVT and pulmonary embolism.
Because Xarelto prevents clotting, its most severe side effect is uncontrolled bleeding that continues until the drug is flushed from the circulatory system. Xarelto has no antidote to slow the bleed and prevent serious harm. It also cannot be flushed out through dialysis.
Patients who have experienced bleeding caused by the drug are hospitalized, and the bleed can sometimes be fatal. Xarelto reacts adversely with an extensive list of other drugs as well.
The Law Office of Jeff Green represents those who have suffered as a result of the use of Xarelto. If you have a Xarelto-related case that requires skillful and determined representation, my team of experts and I will review your claim and discuss the best course of action with you. Contact our office today.
Attorney Jeff Green | (309) 699-0111 | jgreen@jeffgreenlaw.com
-
Xarelto Bleeding Complications a Perfect Storm, Not So Perfect for Patients
Jun 26, 2015 | Lawyers and Settlements
By Gordon Gibb
Washington, DC: As LawyersandSettlements writer Heidi Turner reminds us, it was just over six months ago, on December 15, 2014, that the Xarelto Lawsuit count stood at about 33 in multidistrict litigation for the new-age blood thinner. As of June 15, that number now stands at 552 and climbing in consolidated cases now under the jurisdiction of the Eastern District of Louisiana.
Why?
In what appears to be a perfect storm of sorts, a combination of an aging population requiring blood thinners to ward against stroke and blood clots, a long-sought-after alternative to Coumadin (warfarin), and the small matter of a lack of any means to reverse a Xarelto Bleedout were one to occur is sending scores of patients, their families or their estates to their attorneys.
While Xarelto has yet to achieve the media cache of a drug like Lipitor, a cholesterol-lowering medication that has been skewered in the media in recent years for various side effects including alleged memory loss and confusion, the Xarelto Bleeding Issue is still relatively unknown save for those directly affected.
But it’s a huge story in the making - and one that sounds more like a plot for a movie than the stuff of real-life medicine.
Blood thinners have become a fact of life for a growing number of aging Americans who need to be concerned about arterial plaque, blood clots and the potential for strokes. That blood has to be thinned out a bit, in order to pass through narrowing arteries and veins.
For years, the de facto go-to blood thinner was Coumadin, which is the brand name for warfarin - yes, the same ingredient that goes into the manufacture of rat poison (a rather infamous entry in modern-day pop culture). For some 50 years, Coumadin has ruled the roost. Effective, yes - but also somewhat of a headache, in that strict monitoring of diet and blood has translated into a lot of work for both patient and medical caregiver.
As society does, the search for an easier alternative, with less need for stringent monitoring, has been waged for years. Finally, an answer: first Pradaxa and subsequently Xarelto were given the blessing of the US Food and Drug Administration (FDA) as safe and effective for the intended constituency of patients, for whom the benefits were believed to outweigh the risks.
Happy day, indeed. A blood thinner that was less work, more convenient and less of a hassle for busy patients and their doctors. Oh sure, there are Xarelto side effects - every pharmaceutical drug carries side effects. But the FDA approved it, so all is good.
Right?
Well there is just one little thing…
As with all blood thinners of any stripe, there is always the risk of a bleeding event or hemorrhage if the blood gets too thin and thus refuses to clot in the event of an injury. With Xarelto, there is a risk for Xarelto Bleeding complications as there has been for warfarin. Yes, the exalted Coumadin could also foster a bleeding issue: if monitoring wasn’t stringent enough or there were other factors that came into play to foster a bleed.
But warfarin has an Achilles’ heel in vitamin K: when the latter is immediately infused, the thinning properties of warfarin are quickly reversed and the blood begins to magically clot. As one can appreciate, clots are not your friends when they foster a stroke or other dire medical event. But they can be your best friend after having suffered a deep cut or a serious bruise, or other injury or medical event where bleeding is present and needs that clotting factor in order to stem the flow and save a life.
Xarelto, it seems, was approved without such an antidote in place. Once a serious Xarelto Bleedout begins, it’s almost impossible to stop. This can lead, sadly and tragically, to Xarelto death - or so allege various Xarelto lawsuits.Common to many a Xarelto Lawsuit is the surprise that a reversing agent was not present - that Xarelto would not respond to vitamin K as warfarin does. The confusion is understandable: with Coumadin (warfarin) as the de facto standard for some 50 years, most patients have become accustomed to the reasonable assurance that with warfarin, an unanticipated bleeding event could be stopped. To that end, many Xarelto Bleeding complications plaintiffs allege they had no idea there was no way in which to reverse a Xarelto Bleedout, as there is with warfarin.
Had they known, they would not have chosen the apparent ease and convenience of Xarelto, and instead put up with the required monitoring inherent with warfarin, in exchange for the chance to have a bleeding issue reversed - and perhaps - survive.
The manufacturers and marketers of Xarelto (Rivaroxaban), Janssen and its parent Johnson & Johnson are working on an antidote. It is not known why the FDA approved Xarelto, without one. The Xarelto MDL is In Re: Xarelto Products Liability Litigation, MDL No. 2592, in the US District Court, Eastern District of Louisiana.
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
Add recipients
Suggested